CCDRD AG

CCDRD – Your Partner From Concept to Approval
Founded in 1990, CCDRD is a full-service CRO headquartered near Berlin, with over 35 years of experience and a track record of more than 1,200 Phase I trials and 150 clinical endpoint studies across Europe.
We operate four GCP-inspected Phase I units in Bulgaria and Turkey (EMA & FDA-inspected), complemented by a European clinical network of qualified investigator sites spanning 11 countries in Central and Eastern Europe – covering the full continuum from healthy volunteer studies through to Phase II/III patient trials.
Our expertise covers the full development spectrum:
Regulatory & Strategy: Scientific Advice (EMA, FDA), study design, IND/CTA submissions via CTIS, feasibility evaluations, and medical writing.
Clinical Execution: Phase I–III trials with specialized capabilities in complex formulations – inhalers, transdermals, depot injectables, biosimilars, dermatologicals, and ophthalmologicals. From first-in-human and bioequivalence studies in our own Phase I units to multicenter clinical endpoint studies in qualified centers across our European network. Full site management, patient recruitment, and sponsor reporting.
Data & Quality: Data management, biostatistics, pharmacovigilance, and robust QMS.
Integrated Support: Analytical service oversight, IMP packaging & labeling, logistics, and contracting.
We partner with innovative pharma, specialty generics, and biosimilar developers across Oncology, CNS, Respiratory, Women's Health, Dermatology, Metabolic Diseases, Diabetes, and more – delivering tailored strategies to achieve regulatory approval efficiently and accelerate your path to market.

CCDRD is joining this business trip to connect with pharmaceutical and biotech companies seeking a reliable, experienced CRO partner for their clinical development in Europe. Whether you are planning your first Phase I study, a complex bioequivalence or biosimilar trial, or a multicenter Phase II/III program – we would love to explore how we can support your path to regulatory approval.
We are particularly interested in meeting companies developing complex formulations such as inhalers, transdermal systems, depot injectables, or biosimilars, where our specialized Phase I units and regulatory expertise can add significant value. We also welcome conversations with sponsors looking for cost-efficient, high-quality clinical trial execution in Central and Eastern Europe – whether for early-phase healthy volunteer studies or later-phase patient trials across our European network of qualified investigator sites.
If you are navigating EMA or FDA regulatory pathways and need a partner who can support you from feasibility and Scientific Advice through to final submission – we look forward to meeting you.